new insights into the definitive management of vte
DESCRIPTION
New Insights into the Definitive Management of VTE. Understanding the Burden of VTE. Population-Based Studies: High Incidence of VTE. VTE: An Important Problem Among Hospital Patients. Percentage of Patients at Risk for VTE by Country. - PowerPoint PPT PresentationTRANSCRIPT
New Insights into the Definitive Management of VTE
Understanding the Burden of VTE
Population-Based Studies: High Incidence of VTE
VTE: An Important Problem Among Hospital Patients
Percentage of Patients at Risk for VTE by Country
Percentage of At-Risk Patients Receiving Recommended
Prophylaxis
Pulmonary Embolism Carries a High Mortality Rate
Poor Clinical Outcomes After VTE Treatment
Recurrent VTE is a Common Complication
Incidence of VTE recurrence
VTE Recurrence With Continued vs Shorter VKA Treatment
Incidence of Major Bleeding With Continued vs Shorter VKA
Treatment
Post-thrombotic Syndrome
Patients With VTE are at Risk for Subsequent Development of
Venous Ulcers
Anticoagulant Control and PTS
Chronic Thromboembolic Pulmonary Hypertension
Cost Burden of VTE and Long-Term Complications
Conclusion
Anticoagulant Profiles: What You Need to Know
Currently Available Anticoagulants
Targets of “Classical” Anticoagulants: Heparin and VKAs
Warfarin -- Narrow Therapeutic Window
Challenges and Limitations of VKAs
Risks of Stroke and Mortality Associated With Suboptimal Anticoagulation in AF Patients
Anticoagulation Control and Prediction of Adverse Events in
Patients With AF
The SAMe-TT2R2 score
Targets of NOACs
Absorption and Metabolism of NOACs
NOACs in Chronic Kidney Disease
Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients
With AF
Anticoagulant Profiles: What You Need to Know
At the Crossroads: Deciding Factors for Optimizing VTE
Treatment
Conventional 2-stage Treatment of VTE
New Oral Anticoagulants
Comparisons of Designs of Phase III Acute VTE Trials
RE-COVER I and II:Efficacy and Safety Outcomes
Extended VTE Treatment With Dabigatran
EINSTEIN DVT and PE Trials:Efficacy and Safety Outcomes
EINSTEIN Extension Study
AMPLIFY
Dabigatran, Rivaroxaban, or Apixaban for VTE Treatment
What Have We Learned So Far?
AMPLIFY EXTENSION Study
What Do We Still Need to Know?
Which VTE Patients Are Candidates for New Anticoagulants?
Which VTE Patients Are Not Candidates for New
Anticoagulants?
Where is There Uncertainty for VTE Patients Using New
Anticoagulants?
Opportunities for New Oral Anticoagulants in VTE
Challenges for New Oral Anticoagulants
Conclusions
Recent Clinical Trial Data: Future Opportunities for VTE Prophylaxis and
Treatment
Introduction
Edoxaban
Background Hokusai-VTE Study
Study Outcomes
Baseline Characteristics
Severity Index Event
Efficacy Outcomes
Safety Outcomes
Pre-Specified Subgroups of Interest
Relative Efficacy Over Quartiles of Center
TTR
Relative Efficacy/Safety in 30 mg Dose Group
Conclusion
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)